ziftomenib
kura oncology
['aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'ziftomenib', '$sndx', '$kura', 'kura ']
stifel $kura full presentation of updated ziftomenib r/r npm1m aml data at eha23 confirm highest phase 1 menin inhibitor cr rates (35%)&amp;strong durability (swim-lane plot disclosed). moreover, lack of men1 resistance mutations is a critical element for a second-mover behind $sndx
BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me